Keyphrases
Type 2 Diabetic Patients
100%
Glucagon-like
67%
Bile Acids
50%
Type 2 Diabetes Mellitus (T2DM)
47%
Plasma Concentration
43%
Bile Acid Sequestrants
38%
Placebo
33%
Chenodeoxycholic Acid
25%
Confidence Interval
25%
TGR5
23%
Metformin
23%
Colesevelam
22%
Total Bile Acid
22%
Gallbladder Emptying
22%
Incretin Hormones
20%
Glucose-dependent Insulinotropic Polypeptide
19%
Sulfonylurea
19%
Monotherapy
19%
Glycemic Control
19%
Model Prediction
19%
Thyroid Hormones
19%
Randomized Placebo-controlled Trial
19%
Bile
19%
Meta-analysis of Randomized Controlled Trials
19%
Metabolism
19%
Glucose-lowering Drugs
19%
Systematic Meta-analysis
19%
Liraglutide
19%
Overweight or Obesity
19%
Clinical Significance
19%
Risk of Bias
18%
Fat Content
16%
Adverse Events
15%
Liraglutide 3.0 Mg
15%
Medicine and Dentistry
Patient with Type 2 Diabetes
80%
Glucagon Like Peptide 1
67%
Bile Acid
62%
Secretion (Process)
47%
Bile Acid Sequestrant
38%
Placebo
32%
Maturity Onset Diabetes of the Young
25%
Chenodeoxycholic Acid
24%
Incretin
23%
Colesevelam
22%
Oral Glucose Tolerance Test
20%
Gastric Inhibitory Polypeptide
19%
Glycon
19%
Bile
19%
Receptor
19%
Glycemic Control
19%
Systematic Review with Meta-Analysis
19%
Obesity
19%
Fibroblast Growth Factor 19
19%
Liraglutide
19%
Gallbladder Emptying
19%
Thyrotropin
19%
Randomized Controlled Trial
19%
Fat Content
15%
